An aryl-substituted dihydronaphthalene compound, its preparation method and uses

By synthesizing aryl-substituted dihydronaphthyl compounds, the problems of insufficient selectivity and large side effects of existing PDE4 inhibitors have been solved, providing highly selective and active PDE4B inhibitors for the treatment of psoriasis and other inflammatory diseases, achieving safer and more effective treatment results.

CN117304012BActive Publication Date: 2026-11-10XIANGYA HOSPITAL CENT SOUTH UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311252295.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-26
Publication Date
2026-11-10
Estimated Expiration
2043-09-26

AI Technical Summary

Technical Problem

Existing PDE4 inhibitors have problems such as insufficient selectivity and large side effects when treating psoriasis. They are difficult to effectively inhibit the PDE4B subtype, resulting in poor treatment effects and poor patient compliance.

Method used

A class of aryl-substituted dihydronaphthalene compounds was developed, and highly selective and active PDE4B inhibitors were prepared through specific synthetic methods. The compounds were synthesized using Lewis acid, photocatalysis, and oxidative coupling reactions, and then functionalized to form highly active and selective PDE4B inhibitors.

Benefits of technology

It achieves highly selective inhibition of PDE4B, reduces side effects, and provides a safer and more effective drug option for treating psoriasis and other inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117304012B_ABST
    Figure CN117304012B_ABST
Patent Text Reader

Abstract

This invention relates to an aryl-substituted dihydronaphthalene compound, its preparation method, and its uses. Specifically, this invention relates to a method for preparing an aryl-substituted dihydronaphthalene compound of general formula (I), pharmaceutical compositions containing the derivative, and its use as a therapeutic agent, particularly as a selective inhibitor of phosphodiesterase 4 (PDE4), and in the preparation of medicaments for treating and / or preventing autoimmune diseases, wherein the definitions of each substituent in general formula (I) are the same as those in the specification.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a class of aryl-substituted dihydronaphthalene compounds, their preparation methods, pharmaceutical compositions containing the derivatives, and their use as therapeutic agents, particularly as phosphodiesterase (PDE)4 inhibitors and in the preparation of treatments and / or preventives of PDE4-related diseases. Background Technology

[0002] Globally, autoimmune disease and inflammatory drugs account for 26.4% of annual sales, with an annual prevalence of approximately 5-8%. The Chinese market for autoimmune disease drugs is growing significantly faster than the global average, with nearly 7 million people suffering from psoriasis and nearly 6.5 million from rheumatoid arthritis, indicating enormous market potential. The physical and mental health problems caused by autoimmune diseases are receiving increasing attention, becoming a major threat to people's healthy lives. Major global drug development centers are placing great emphasis on the research and development of drugs for autoimmune diseases.

[0003] Taking psoriasis as an example, twenty years ago, the treatment of psoriasis mainly relied on topical corticosteroids (for mild cases) and methotrexate (for severe cases). Traditional psoriasis medications, such as corticosteroids, were limited to topical use. However, psoriasis is a systemic chronic inflammatory disease, and long-term use had poor safety profiles and patient compliance. With the introduction of a series of specific targeted biologics, such as tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors, psoriasis has significantly improved. However, these targeted biologics can only inhibit overactivated cytokines and cannot treat psoriasis at its root. Furthermore, there are currently only four small-molecule drugs marketed for psoriasis: the PDE4 (Phoshodiesterase 4) inhibitor Apremilast (oral), Roflumilast (topical), the TYK2 inhibitor deucravacitinib (oral), and the AhR inhibitor benvimod (topical). TYK2 belongs to the JAK subtype. The FDA requires the addition of a boxed warning in the product information label stating "increased risk of serious cardiac events, cancer, thrombosis, and death," severely limiting its clinical use. AhR inhibitors like benvimod have weak activity and significant side effects. PDE4 inhibitors exist in four subtypes (A, B, C, and D), such as Roflumilast, which has only 1.2-fold selectivity for PDE4B / PDE4D subtypes and causes severe side effects like nausea and vomiting. Psoriasis, still known as "cowhide rash," commonly experiences relapse and secondary drug resistance upon discontinuation of medication. The demand for new drugs targeting key pathways in psoriasis and related inflammatory diseases using small molecule drugs remains strong. Therefore, there is an urgent need to develop new alternative treatments. This patent addresses this by discovering a new, highly active and selective PDE4B inhibitor for oral administration, which is safe, effective, and provides long-term relief from psoriasis progression.

[0004] PDEs catalyze the hydrolysis and inactivation of cAMP, playing a central role in cAMP-mediated signal regulation, determining the duration and intensity of downstream cAMP signals, while cAMP broadly regulates normal cellular physiological activities. Studies have shown that high expression of PDE4 drives a significant increase in the secretion of pro-inflammatory factors such as tumor necrosis factor-α (TNF-α), interleukins IL-12, IL-17, IL-22, IL-23, and interferon IFN-γ in psoriasis patients. High expression of PDE4 leads to a decrease in intracellular cAMP concentration. Once cAMP is inactivated, it cannot transduce signals to protein kinase A (PKA) and cannot activate cAMP response element-binding protein (CREB). This prevents IL-2, IL-6, IL-10, and TNF-α from binding to CREB, disrupting their homeostatic balance and promoting the pathophysiological development of psoriasis. Multiple pro-inflammatory factors are persistently overexpressed, slowly damaging the entire skin and ultimately progressing to psoriasis characterized by silvery, erythematous plaques. Inhibiting PDE4 can suppress the production and secretion of various inflammatory factors such as IFN-γ, TNF-α, IL-2, IL-12, and IL-23, as well as chemokines and peroxides. Simultaneously, it upregulates the anti-inflammatory factor IL-10 by activating CREB. The successful FDA approval of Apremilast and Roflumilast for the treatment of psoriasis patients signifies that PDE4 has been recognized as a clinically validated drug target for psoriasis.

[0005] PDE4 has four subtypes: PDE4A, PDE4B, PDE4C, and PDE4D. These subtypes differ not only in distribution and expression but also in their biological effects. The work of Conti's group identified PDE4B as the main PDE4 enzyme involved in the pro-inflammatory response of macrophages and leukocytes to LPS (lipopolysaccharide), while PDE4D is associated with numerous adverse reactions such as nausea and vomiting. The main reason is that PDE4D is expressed not only in immune cells but also highly in the nucleus tractus solitarius and the last zone (the main emetic region) of the medulla oblongata. Therefore, the most common side effects of PDE4 inhibitors, due to their inhibition of PDE4D, are nausea, vomiting, and headache. The highly conserved catalytic domains and very similar active sites among the PDE4 subtypes are a key reason why specific and selective inhibitors of PDE4B have not been successfully developed for clinical use for many years. Therefore, a deeper understanding of the PDE4 subtypes and the development of highly selective and highly active inhibitors of PDE4B are crucial for drug development for clinically unmet needs in inflammatory diseases such as psoriasis. Summary of the Invention

[0006] This invention discloses for the first time a novel preparation method for phenyl-substituted dihydronaphthalene derivatives and compounds exhibiting PDE4 inhibitory activity. This invention designs small-molecule PDE4B selective antagonists with higher activity and demonstrates superior efficacy and effects. These compounds can be used to effectively treat psoriasis and other autoimmune diseases or inflammatory conditions.

[0007] One aspect of the present invention provides an aryl-substituted dihydronaphthalene compound having the general formula (I) or a derivative thereof:

[0008]

[0009] The derivatives of the compound are at least one of its tautomers, meso, racemic, enantiomers, diastereomers, or pharmaceutically acceptable salts thereof.

[0010] in:

[0011] R1 and R2 are each independently selected from hydrogen, aldehyde, hydroxyl, cyano, nitro, amino, ester, haloalkane, aryl, heteroaryl, and their hydroxyalkyl, alkoxy, alkylamine, alkamido, and alkylsulfonamide groups, wherein the alkyl group is optionally C1-6 alkyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclic; wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each optionally substituted by one or more substituents selected from halogen, cyano, nitro, amino, hydroxyl, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, alkoxy, and alkylamine groups;

[0012] R3, R4, R5, R6, R7, and R8 are independently selected from hydrogen, halogen, hydroxyl, amino, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkoxy, and 3- to 6-membered heterocyclic alkoxy. R3 and R4 or R5 and R6 can be linked together to form a ring via -oxy-C1-3 alkyl-oxy-.

[0013] Preferably, R7 and R8 are hydrogen.

[0014] Preferably, R3, R4, R5, and R6 are selected from hydrogen, hydroxyl, halogen, C1-3 alkoxy, C1-3 cycloalkoxy, and R3-R4 and R5-R6 are linked by an oxygen ether bond to form a methylenedioxy or a substituted methylenedioxy.

[0015] Based on a general inventive concept, embodiments of the present invention provide a method for preparing an aryl-substituted dihydronaphthalene compound as shown in the figure below; wherein, the key step is the preparation of compound IA by the first-of-its-kind catalytic synthesis method of general formula (IB);

[0016] Compounds of general formula IA undergo a coupling reaction under oxidative conditions to yield compounds of general formula (IB), as detailed below:

[0017] Method 1: Oxidative coupling reaction under Lewis acid activation or ligand coordination activation yields compounds of general formula (IB);

[0018] Alternatively, method two: under photocatalysis, oxidative coupling reaction yields compounds of general formula (IB);

[0019] Alternatively, method three: under catalytic Lewis acid activation or ligand coordination activation, combined with a photocatalytic system, an oxidative coupling reaction is carried out to obtain a compound of general formula (IB);

[0020] Various general formulas (IC) and (I) can be obtained by modifying them with different functional groups.

[0021] Lewis acids include, but are not limited to, V(acac)₂, AlCl₃, BF₃, SbCl₅, FeBr₃, FeCl₃, SnCl₄, TiCl₄, Ti(iPrO)₄, ZnCl₂, Cu(CH₃CN)PF₆, CuI, CuBr, CuCl, CuCN, CuBr₂, CuCl₂, CuBrMe₂S, Cu(CH₃CN)BF₄, Cu(OTf)₂, Cu(SO₄)₂, MnO₂, Fe(OTf)₃, Sc(OTf)₃, etc. V(acac)₂ and Cu(CH₃CN)PF₆ are preferred Lewis acids.

[0022] Photosensitizers include, but are not limited to, [Ir(dF(CF3)ppy)2(dtbpy)]PF6, tris[2-phenylpyridine-C2,N]iridium(III), Ir[dF(CF3)ppy]2(dtbbpy)PF6, [Ir[dF(CF3)2ppy]2(bpy)]PF6, Ir(pF-ppy)3, tris(2,2'-bipyridine)ruthenium dichloride, tris(1,10-phenanthroline)ruthenium(II) hexafluorophosphate, tris[4,4'-bis(tert-butyl)-2,2'-bipyridine]ruthenium(II) hexafluorophosphate, dimethylglyoxane, and ferrocene. The preferred photosensitizer is [Ir(dF(CF3)ppy)2(dtbpy)]PF6.

[0023] The reagents providing the oxidizing conditions include oxygen, air, and other oxidizing agents, including but not limited to hydrogen peroxide (H₂O₂), tert-butanol peroxide (tBuO₂H), benzoyl peroxide, FeCl₃, Cu(OTf)₂, and MnO₂. Oxygen and air are preferred as the oxidizing agents.

[0024] Acid additives include acetic acid, propionic acid, butyric acid, valeric acid, benzoic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, phosphoric acid, chiral phosphoric acid, molecular sieves, etc.

[0025] Alkali additives include triethylamine, pyridine, diisopropylethylamine, potassium carbonate, sodium carbonate, sodium benzoate, sodium bicarbonate, potassium bicarbonate, sodium sulfate, and ammonium sulfate.

[0026] The solvents used include, but are not limited to: trifluoroethanol, hexafluoroisopropanol, acetic acid, methanol, ethanol, isopropanol, toluene, fluorobenzene, chlorobenzene, tetrahydrofuran, dichloromethane, dichloroethane, o-dichlorobenzene, dimethyl sulfoxide, 1,4-dioxane, water, or N,N-dimethylformamide.

[0027]

[0028] Another embodiment of the present invention provides a pharmaceutical composition containing a therapeutically effective amount of the above-described aryl-substituted dihydronaphthalene compound, a pharmaceutically acceptable carrier, a diluent, and an excipient.

[0029] Embodiments of the present invention also provide the use of the above-described pharmaceutical composition in the preparation of a treatment for the prevention and / or treatment of autoimmune diseases, said autoimmune diseases being psoriasis, psoriatic arthritis, atopic dermatitis, eczema, alopecia areata, depression, multiple sclerosis, scleroderma, chronic obstructive pulmonary disease, pulmonary fibrosis, rhinitis, asthma, Crohn's disease, rheumatoid arthritis, ulcerative colitis, or other diseases related to the phosphodiesterase 4 (PDE4) pathway.

[0030] Embodiments of the present invention also provide the use of the above-described aryl-substituted dihydronaphthalene compound in combination with an immune checkpoint inhibitor in the preparation of a treatment for the prevention and / or treatment of diseases affected by PDE4 inhibition.

[0031] Preferably, the diseases affected by PDE4 inhibition are psoriasis or pulmonary fibrosis.

[0032] Preferably, the compounds of general formula (I) include, but are not limited to, the following compounds:

[0033] Attached Figure Description

[0034] Figure 1 This is the structural formula of a general formula (I) of an aryl-substituted dihydronaphthalene compound in an embodiment of the present invention;

[0035] Figure 2 This is a synthetic route for an aryl-substituted dihydronaphthalene compound in an embodiment of the present invention;

[0036] Figure 3This is a test PDE4 inhibition activity diagram of Example 4 of the present invention. Detailed Implementation

[0037] The present invention will be further described below with reference to embodiments and accompanying drawings, but these embodiments are not intended to limit the scope of the present invention.

[0038] The structures of the compounds mentioned in the following embodiments of the present invention were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) are given in units of 10⁻⁶ (ppm). NMR measurements were performed using Bruker AVANCE-400, Bruker AVANCE-500, and Bruker AVANCE-600 NMR spectrometers, with deuterated dimethyl sulfoxide (DMSO-d₆), deuterated chloroform (CDCl₃), and deuterated methanol (CD₃OD) as solvents, and tetramethylsilane (TMS) as the internal standard.

[0039] Thin-layer chromatography silica gel plates are Yantai Huanghai HSGF254 or Qingdao GF254. The silica gel plates used in thin-layer chromatography (TLC) have a diameter of 0.15 mm to 0.2 mm, and the diameter of the silica gel plates used for thin-layer chromatography separation and purification products is 0.4 mm to 0.5 mm.

[0040] Column chromatography typically uses Yantai Huanghai silica gel with a mesh size of 200-300 as the carrier.

[0041] The known starting materials of this invention can be synthesized using or according to methods known in the art, or can be purchased from companies such as Innovent Biologics, Biologics, Adamas, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc., Sinopharm, and Aladdin.

[0042] Unless otherwise specified in the examples, the reactions can be carried out under an argon or nitrogen atmosphere.

[0043] Argon or nitrogen atmosphere refers to a reaction vessel connected to an argon or nitrogen gas balloon or cylinder with a volume of approximately 1L.

[0044] Unless otherwise specified in the examples, "solution" refers to an aqueous solution.

[0045] Unless otherwise specified in the examples, the reaction temperature is room temperature, which is 20℃~30℃.

[0046] The reaction process in the examples was monitored using thin-layer chromatography (TLC). The developing solvent systems used in the reactions were: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether and ethyl acetate system, and D: acetone. The volume ratio of the solvents was adjusted according to the polarity of the compounds.

[0047] The eluent systems for column chromatography and the developing solvent systems for thin-layer chromatography used to purify the compounds include: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, and C: dichloromethane and acetone system. The volume ratio of the solvents is adjusted according to the polarity of the compounds, and small amounts of basic or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.

[0048] To address the aforementioned problems in the background art, one aspect of the embodiments of the present invention provides an aryl-substituted dihydronaphthalene compound having the general formula (I) shown in the figure (e.g., Figure 1 (as shown) or its derivatives:

[0049]

[0050] The derivatives of the compound are at least one of its tautomers, meso, racemic, enantiomers, diastereomers, or pharmaceutically acceptable salts thereof.

[0051] in:

[0052] R1 and R2 are each independently selected from hydrogen, aldehyde, hydroxyl, cyano, nitro, amino, ester, haloalkane, aryl, heteroaryl, and their hydroxyalkyl, alkoxy, alkylamine, alkamido, and alkylsulfonamide groups, wherein the alkyl group is optionally C1-6 alkyl, 5-6 membered heteroaryl, or 5-6 membered heterocyclic; wherein the cycloalkyl, heterocyclic, aryl, and heteroaryl groups are each optionally substituted by one or more substituents selected from halogen, cyano, nitro, amino, hydroxyl, alkyl, haloalkyl, hydroxyalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, alkoxy, and alkylamine groups;

[0053] R3, R4, R5, R6, R7, and R8 are independently selected from hydrogen, halogen, hydroxyl, amino, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkoxy, and 3- to 6-membered heterocyclic alkoxy. R3 and R4 or R5 and R6 can be linked together to form a ring via -oxy-C1-3 alkyl-oxy-.

[0054] Preferably, R7 and R8 are hydrogen.

[0055] Preferably, R3, R4, R5, and R6 are selected from hydrogen, hydroxyl, halogen, C1-3 alkoxy, C1-3 cycloalkoxy, and R3-R4 and R5-R6 are linked by an oxygen ether bond to form a methylenedioxy or a substituted methylenedioxy.

[0056] Based on a general inventive concept, embodiments of the present invention provide a method for preparing the above-mentioned aryl-substituted dihydronaphthalene compound, the method being as follows: Figure 2 The key step is the preparation of compound IA using the first-ever catalytic synthesis method, which yields the general formula (IB).

[0057] Compounds of general formula IA undergo a coupling reaction under oxidative conditions to yield compounds of general formula (IB), as detailed below:

[0058] Method 1: Oxidative coupling reaction under Lewis acid activation or ligand coordination activation yields compounds of general formula (IB);

[0059] Alternatively, method two: under photocatalysis, oxidative coupling reaction yields compounds of general formula (IB);

[0060] Alternatively, method three: under catalytic Lewis acid activation or ligand coordination activation, combined with a photocatalytic system, an oxidative coupling reaction is carried out to obtain a compound of general formula (IB);

[0061] Various general formulas (IC) and (I) can be obtained by modifying them with different functional groups.

[0062] Lewis acids include, but are not limited to, V(acac)₂, AlCl₃, BF₃, SbCl₅, FeBr₃, FeCl₃, SnCl₄, TiCl₄, Ti(iPrO)₄, ZnCl₂, Cu(CH₃CN)PF₆, CuI, CuBr, CuCl, CuCN, CuBr₂, CuCl₂, CuBrMe₂S, Cu(CH₃CN)BF₄, Cu(OTf)₂, Cu(SO₄)₂, MnO₂, Fe(OTf)₃, Sc(OTf)₃, etc. V(acac)₂ and Cu(CH₃CN)PF₆ are preferred Lewis acids.

[0063] Photosensitizers include, but are not limited to, [Ir(dF(CF3)ppy)2(dtbpy)]PF6, tris[2-phenylpyridine-C2,N]iridium(III), Ir[dF(CF3)ppy]2(dtbbpy)PF6, [Ir[dF(CF3)2ppy]2(bpy)]PF6, Ir(pF-ppy)3, tris(2,2'-bipyridine)ruthenium dichloride, tris(1,10-phenanthroline)ruthenium(II) hexafluorophosphate, tris[4,4'-bis(tert-butyl)-2,2'-bipyridine]ruthenium(II) hexafluorophosphate, dimethylglyoxane, and ferrocene. The preferred photosensitizer is [Ir(dF(CF3)ppy)2(dtbpy)]PF6.

[0064] The reagents providing the oxidizing conditions include oxygen, air, and other oxidizing agents, including but not limited to hydrogen peroxide (H₂O₂), tert-butanol peroxide (tBuO₂H), benzoyl peroxide, FeCl₃, Cu(OTf)₂, and MnO₂. Oxygen and air are preferred as the oxidizing agents.

[0065] Acid additives include acetic acid, propionic acid, butyric acid, valeric acid, benzoic acid, trifluoroacetic acid, methanesulfonic acid, p-toluenesulfonic acid, phosphoric acid, chiral phosphoric acid, molecular sieves, etc.

[0066] Alkali additives include triethylamine, pyridine, diisopropylethylamine, potassium carbonate, sodium carbonate, sodium benzoate, sodium bicarbonate, potassium bicarbonate, sodium sulfate, and ammonium sulfate.

[0067] The solvents used include, but are not limited to: trifluoroethanol, hexafluoroisopropanol, acetic acid, methanol, ethanol, isopropanol, toluene, fluorobenzene, chlorobenzene, tetrahydrofuran, dichloromethane, dichloroethane, o-dichlorobenzene, dimethyl sulfoxide, 1,4-dioxane, water, or N,N-dimethylformamide.

[0068]

[0069] Another embodiment of the present invention provides a pharmaceutical composition containing a therapeutically effective amount of the above-described aryl-substituted dihydronaphthalene compound, a pharmaceutically acceptable carrier, a diluent, and an excipient.

[0070] Embodiments of the present invention also provide the use of the above-described pharmaceutical composition in the preparation of a treatment for the prevention and / or treatment of autoimmune diseases, said autoimmune diseases being psoriasis, psoriatic arthritis, atopic dermatitis, eczema, alopecia areata, depression, multiple sclerosis, scleroderma, chronic obstructive pulmonary disease, pulmonary fibrosis, rhinitis, asthma, Crohn's disease, rheumatoid arthritis, ulcerative colitis or other PDE4 pathway-related diseases.

[0071] Embodiments of the present invention also provide the use of the above-described aryl-substituted dihydronaphthalene compound in combination with an immune checkpoint inhibitor in the preparation of a treatment for the prevention and / or treatment of diseases affected by PDE4 inhibition.

[0072] Preferably, the diseases affected by PDE4 inhibition are psoriasis or pulmonary fibrosis.

[0073] Typical compounds of general formula (I) of this invention include, but are not limited to:

[0074]

[0075]

[0076] Example 1 will be described in detail through the following examples:

[0077]

[0078] Dimethyl1-(3,4-dihydroxyphenyl)-6,7-dihydroxy-1,2-dihydronaphthalene-2,3-dicarboxylate

[0079] Catalyst Cu(CH3CN)4PF6 (0.1 equiv), ligand o-phenanthroline (0.1 equiv), and benzoic acid (0.1 equiv) were dissolved in a 1:1 DCE / TFE mixed solvent. 3-(3,4-dihydroxyphenyl)-methyl ester was added under oxygen protection, and the reaction was carried out at 40 °C for 24 h. Extraction was performed using EA, followed by drying to anhydrous sodium sulfate, filtration, concentration of the filtrate, and rapid column chromatography to separate the product, yielding compound 1-(3,4-dihydroxyphenyl)-1,2-dihydro-6,7-dihydroxy-2,3-dimethyl ester in 80% yield.

[0080] The nuclear magnetic resonance data of Example 1 are as follows: 1 H NMR (600MHz, DMSO-d6) δ10.01(s,1H),8.73(s,1H),8.67(s,1H),8.56(s,1H),7.64(s,1H),6.90(d,J=8.0Hz,1H),6.75(d,J=8.1Hz,1H), 6.56(d,J=8.1Hz,1H),6.34(d,J=2.1Hz,1H),6.27(dd,J=8.1,2.2Hz,1H),4.78(s,1H),3.76(d,J=1.3Hz,1H),3.66(s,3H),3.57(s,3H). 13 C NMR (151MHz, DMSO) δ172.24,166.78,148.18,144.82,143.88,142.78,138.70,133.65,123.49 ,123.45,121.51,119.87,117.91,115.40,114.63,113.64,52.27,51.70,48.70,46.79,38.68.

[0081] Example 2:

[0082]

[0083] Dimethyl 1-(3,4-dimethoxyphenyl)-6,7-dimethoxy-1,2-dihydronaphthalene-2,3-dicarboxylate was dissolved in Acetone under N2 protection. K2CO3 (20 equiv) was added, followed by the addition of MeI (20 equiv) under N2 protection. The mixture was refluxed overnight at 57°C. After the reaction was complete, the K2CO3 was filtered off, the filtrate was concentrated, extracted three times with DCM, washed twice with H2O, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and purified by rapid column chromatography to give compound 1-(3,4-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-dimethyl ester in 48% yield.

[0084] The nuclear magnetic resonance data for Example 2 are as follows: 1 H NMR (600MHz, DMSO-d6) δ7.70(s,1H),7.33(d,J=8.3Hz,1H),7.05(d,J=8.3Hz,1H),6.77(s,1H),6.72(d,J=8.2Hz,1H ),6.22(d,J=8.4Hz,1H),4.96(s,1H),3.96(s,1H),3.84(s,3H),3.67(s,6H),3.64(s,3H),3.56(s,3H),3.49(s,3H). 13 C NMR (151MHz, DMSO) δ171.64,166.38,154.69,148.54,147.54,145.79,137.40,134.18,130.27,125.99,1 24.64,121.68,118.87,111.55,111.50,111.17,59.92,55.75,55.45,55.36,52.32,51.81,45.88,38.62.

[0085] Example 3:

[0086]

[0087] 1-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-1,2-dihydronaphthalene-2,3-diyl)dim ethanol

[0088] 1-(3,4-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-dimethyl ester was dissolved in THF and reacted with LiAlH4 (6 equiv) at 0 °C for 1 h. The reaction was quenched with Acetone at 0 °C, and saturated NH4Cl aqueous solution was added, with stirring continued until distinct layers formed. The mixture was extracted three times with Et2O, dried over anhydrous sodium sulfate, filtered to remove the sodium sulfate, concentrated, and purified by rapid column chromatography to give compound 1-(3,4-dimethoxyphenyl)-6,7-dimethoxy-1,2-dihydronaphthalene-2,3-diyl)diethanol in 55% yield.

[0089] The nuclear magnetic resonance data for Example 3 are as follows: 1 H NMR(600MHz,Chloroform-d)δ6.86(d,J=8.2Hz,1H),6.76(d,J=8.2Hz,1H),6.68(s,1H),6.62(d,J=8.3Hz,1H),6.46(d,J=7.6Hz,2H),4.48( s,1H),4.05(d,J=12.9Hz,1H),3.95(d,J=12.9Hz,1H),3.82(s,3H),3.76(s,6H),3.52(d,J=7.2Hz,2H),3.45(s,3H),2.64(t,J=7.3Hz,1H). 13 C NMR (151MHz, CDCl3) δ152.67,148.59,147.34,146.84,136.46,136.35,129.83,126.99,124.73,1 22.66,119.58,111.16,110.87,110.59,66.32,65.24,60.61,55.87,55.80,55.68,47.12,38.99.

[0090] Example 4:

[0091]

[0092] 4-(3,4-Dimethoxyphenyl)-3-(hydroxymethyl)-6,7-dimethoxy-3,4-dihydronapht

[0093] halene-2-carbaldehyde

[0094] 1-(3,4-dimethoxyphenyl)-6,7-dimethoxy-1,2-dihydronaphthalene-2,3-diyl)diethanol was dissolved in DMF, and PDC (1.5 equiv) was added. The mixture was reacted at room temperature for 5 h. EA was added, and the mixture was washed three times with water. Extraction was performed with EA, dried over anhydrous sodium sulfate, filtered through anhydrous sodium sulfate, and the filtrate was concentrated. Rapid column chromatography was used to purify the compound 4-(3,4-dimethoxyphenyl)-3,4-dihydro-3-hydroxymethyl-6,7-dimethoxy in 80% yield.

[0095] The nuclear magnetic resonance data for Example 4 are as follows: 1 H NMR(600MHz,Chloroform-d)δ9.50(s,1H),7.31(s,1H),7.14(d,J=8.3Hz,1H),6.85(d,J=8.3Hz,1H),6.67(s,1H),6.58(d,J=8.3Hz,1H),6.3 6(d,J=8.3Hz,1H),4.78(s,1H),3.85(s,3H),3.74(s,3H),3.73(s,3H),3.54(dd,J=9.4,4.5Hz,1H),3.50(s,3H),3.29(pd,J=8.6,2.7Hz,2H). 13 C NMR (151MHz, CDCl3) δ193.02,155.87,148.70,147.44,147.30,146.53,136.15,135.62,132.88,1 26.03,125.05,119.28,111.09,110.87,110.77,63.65,60.56,55.81,55.76,55.73,42.05,37.65.

[0096] Example 5:

[0097]

[0098] Dimethyl

[0099] 5-(2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-2,2-dimethyl-5,6-dihydronaphtho[2,3-d][1,3]dioxole-6,7-dicarboxylate

[0100] 1-(3,4-dihydroxyphenyl)-1,2-dihydro-6,7-dihydroxy-2,3-dimethyl ester was dissolved in CHCl3, and p-toluenesulfonic acid (0.1 equiv) and 2,2-methoxypropane (6 equiv) were added. The mixture was refluxed at 62 °C for 18 h, and then neutralized with saturated NaHCO3. The mixture was extracted three times with DCM, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by rapid column chromatography to obtain dimethyl-5-(2,2-dimethylbenzo[d][1,3]dihydroxy-5-yl)-2,2-dimethyl-5,6-dihydronaphtho[2,3-d][1,3]dihydroxy-6,7-dicarboxylic acid ester in 45% yield.

[0101] The nuclear magnetic resonance data for Example 5 are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.67(s,1H),6.84(d,J=7.9Hz,1H),6.63(d,J=7.9Hz,1H),6.53(d,J=7.0Hz,2H),6.5 0(s,1H),4.76(s,1H),4.05(s,1H),3.77(s,3H),3.66(s,3H),1.68(s,4H),1.62(s,3H),1.61(s,4H),1.54(s,3H). 13 C NMR (151MHz, CDCl3) δ172.62,167.38,149.76,147.49,146.27,145.43,138.17,135.41,130.01,128.22,125.37,123.74,121. 66,119.72,119.20,117.88,117.82,107.92,107.65,107.26,77.37,77.16,76.95,52.63,52.06,46.09,39.36,26.03,26.01.

[0102] Example 6:

[0103]

[0104] Dimethyl5-(benzo[d][1,3]dioxol-5-yl)-5,6-dihydronaphtho[2,3-d][1,3]dioxole-6,7-dicarboxyl ate

[0105] 1-(3,4-dihydroxyphenyl)-1,2-dihydro-6,7-dihydroxy-2,3-dimethyl ester was dissolved in DMF, and CsF was added. The reaction was carried out at 115℃ for 2.5 h, followed by the addition of DCM and a further 6 h of reaction. The reaction was quenched with water, extracted three times with EA, and the organic layer was washed with saturated NaHCO3 solution, followed by washing twice with H2O and NH4Cl. The mixture was dried over Na2SO4, concentrated, and column chromatography was used to obtain dimethyl-5-(benzo[d][1,3]dihydroxy-5-yl)-5,6-dihydronaphtho[2,3-d][1,3]dihydroxy-6,7-dicarboxylic acid ester, with a yield of 40%.

[0106] The nuclear magnetic resonance data for Example 6 are as follows: 1 H NMR(600MHz,Chloroform-d)δ7.70(s,1H),6.91(d,J=7.9Hz,1H),6.73(d,J=7.9Hz,1H),6.66(d,J=7.9Hz, 1H), 6.57 (d, J = 11.6Hz, 2H), 5.95 (s, 2H), 5.88 (s, 2H), 4.82 (s, 1H), 4.02 (s, 1H), 3.77 (s, 3H), 3.67 (s, 3H). 13 C NMR (151MHz, CDCl3) δ172.41,167.17,149.91,147.82,146.64,145.45,137.78,135.61,125.92,124.24,122.0 2,120.48,117.71,108.41,107.92,107.53,101.93,101.10,77.37,77.16,76.95,52.74,52.11,46.28,39.44.

[0107] Biological evaluation

[0108] The present invention will be further described and explained below with reference to test examples, but these test examples are not intended to limit the scope of the present invention.

[0109] Experimental methods in the test examples of this invention that do not specify specific conditions are generally performed under conventional conditions or as recommended by the product manufacturer. Reagents whose specific source is not specified are commercially available, conventional reagents.

[0110] Reagent preparation:

[0111] Enzymes: PDE4B1 (324-659), PDE4A, PDE4C, PDE4D 1μM, purified in our laboratory, working solution concentration 250nM.

[0112] Substrate: cAMP (MCE: HY-B1511), stock solution concentration 5 mM (solvent: ddH2O), working solution concentration 100 μM

[0113] CIAP (Takara: 2205A, 30 U / μl), working solution concentration: 1.5 u / ml

[0114] Malachite Green Phosphate DetectionKit (Biyuntian: S0196M)

[0115] Enzyme reaction buffer: 100mM Tris-HCl (pH 7.5), NaCl (150mM), both prepared using enzyme reaction buffer to form the above working solution.

[0116] Compounds: A gradient of VB-6 derivatives was prepared at concentrations of (10 μM, 1 μM, 0.1 μM, 0.01 μM, 0.001 μM, 0.0001 μM, 0.00001 μM).

[0117] The experimental steps are detailed below:

[0118] 1. Take 2 μl of each compound or solvent of different concentrations into a 96-well plate;

[0119] 2. Add 89 μl of 250 nM enzyme PDE4B1 (324-659) and operate on ice;

[0120] 3. Add 89 μl of 100 μM cAMP;

[0121] 4. Add 20 μl of 1.5 U / ml CIAP;

[0122] 5. Let stand at room temperature for 2 hours;

[0123] 6. Add 70 μl of Malachite Green working solution, react at room temperature for 30 min, detect the OD value at 630 nm, and use GraphPad to perform curve fitting and obtain IC50.

[0124] Conclusion: The compounds of this invention exhibit significant inhibitory activity against PDE4B.

[0125] The positive control compound was Apremilast.

[0126] The PDE4B inhibitory activity data of some of the above compounds are as follows (Table 1):

[0127] Entry PDE4B inhibitory activity (IC50) Apremilast B Example 1 B Example 2 A Example 3 A Example 4 B Example 5 A

[0128] Among them, A: >300nM, B: <300nM

[0129] Finally, taking Example 4 as an example, we investigated its PDE4 selectivity and tested the inhibitory activity of Example 4 on each PDE4 subtype according to the above bioactivity test method.

[0130] The results showed that (e.g.) Figure 3 As shown), Example 4 (VB-6) showed no inhibitory activity against PDE4C and PDE4D, but had weak activity against PDE4A, and significant inhibitory activity against PDE4B (IC50 = 11 nM).

Claims

1. An aryl-substituted dihydronaphthalene compound, selected from compounds with the following chemical structural formula: or .

2. A pharmaceutical composition comprising a therapeutically effective amount of the aryl-substituted dihydronaphthalene compound of claim 1, a pharmaceutically acceptable carrier, a diluent, and an excipient.

3. Use of the pharmaceutical composition of claim 2 in the preparation of a product for the prevention and / or treatment of an autoimmune disease, wherein the autoimmune disease is psoriasis, psoriatic arthritis, atopic dermatitis, eczema, alopecia areata, depression, multiple sclerosis, scleroderma, chronic obstructive pulmonary disease, pulmonary fibrosis, rhinitis, asthma, Crohn's disease, rheumatoid arthritis, ulcerative colitis or other diseases related to the phosphodiesterase 4 (PDE4) pathway.

4. Use of an aryl-substituted dihydronaphthalene compound as described in claim 1 in combination with an immune checkpoint inhibitor in the preparation of a product for the prevention and / or treatment of diseases affected by PDE4 inhibition.

5. The use according to claim 4, wherein the disease affected by inhibiting PDE4 is psoriasis or pulmonary fibrosis.